Tillkännagivande • 2m
Repligen Corporation (NasdaqGS:RGEN) entered into an agreement and plan of merger to acquire BioLife Solutions, Inc. (NasdaqCM:BLFS) for approximately $1.6 billion. Repligen Corporation (NasdaqGS:RGEN) entered into an agreement and plan of merger to acquire BioLife Solutions, Inc. (NasdaqCM:BLFS) for approximately $1.6 billion on July 21, 2026. BioLife stockholders will receive $11.25 per share in cash and 0.1442 shares of Repligen common stock, which equates to a total value of $31.00 per share, represented BioLife’s enterprise value of approximately $1.5 billion, comprised of 64% in Repligen common stock and 36% in cash (the “Transaction”). The transaction includes approximately $560 million in cash and 7.2 million Repligen shares. This represents an implied premium of 24% to 90-day volume-weighted average price (VWAP) for the period ended July 21, 2026. The enterprise value of $1.5 billion involves 11x 2027E Revenue with an EV/EBITDA multiple on a fully synergized basis. Cash portion is funded from cash on hand. Pursuant to the Merger Agreement, and subject to the satisfaction or waiver of the conditions specified therein, Merger Sub 1 will be merged with and into BioLife (the “First Merger”), with BioLife surviving the First Merger as a direct, wholly owned subsidiary of Repligen. 160 associates of BioLife Solutions will join RGEN team at closing. Following a termination set forth in clause (I) or (II), within 12 months of the termination date, BioLife enters into a definitive agreement for, or consummates, a competing transaction proposal, BioLife may be required to pay Repligen a termination fee of $59 million.
The consummation of the Mergers is subject to customary closing conditions, including (among others); the adoption and approval of the Merger Agreement by the holders of a majority of the outstanding shares of BioLife Common Stock entitled to vote thereon, the absence of any adverse law or order that restrains, enjoins, makes illegal or otherwise prohibits the consummation of the Mergers (the “Restraint Condition”), the shares of Repligen common stock to be issued in the First Merger being approved for listing on The Nasdaq Stock Market, the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), and the receipt of consents required under antitrust laws of specified jurisdictions (the “Antitrust Condition”) and the U.S. Securities and Exchange Commission (the “SEC”) having declared effective the Registration Statement on Form S-4 to be filed by Repligen, which will contain the proxy statement/prospectus of the parties in connection with the Mergers. The boards of directors of each of Repligen and BioLife have approved the Merger Agreement and the transactions contemplated thereby. The parties expect that the Mergers will be completed in the fourth quarter of 2026, subject to satisfaction of customary closing conditions. The transaction is accretive to both revenue growth and margins and year adj.EPS - stock/cash mix preserves flexibility.
Perella Weinberg and Goldman Sachs & Co. LLC are serving as financial advisors and Stuart M. Cable, Jacqueline Mercier and Tevia K. Pollard of Goodwin Procter are serving as legal counsel to Repligen. Centerview Partners, LLC is serving as financial advisor and fairness opinion provider and Michael A. Hedge and Jason C. Dreibelbis of K&L Gates LLP are serving as legal counsel to BioLife. Buy Or Sell Opportunity • Jul 17
Now 23% undervalued Over the last 90 days, the stock has risen 36% to US$29.15. The fair value is estimated to be US$37.71, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 14% over the last 3 years. Earnings per share has grown by 100%. Live-nyheter • Jun 22
BioLife Solutions Rallies as Growth Focus Shifts to Biopreservation Media Segment BioLife Solutions has shifted away from an acquisition-led approach to concentrate on its core biopreservation media products, which supply the cell and gene therapy market and are described as a high-margin, high-growth segment expected to deliver over 20% annual growth.
The refocus is framed as a material change in corporate direction, with management aiming for improved long-term profitability and clearer positioning around biopreservation media rather than a wider collection of acquired assets.
BioLife Solutions’ stock trades at $26.04, with a 90-day return of 32.2%, indicating a strong rebound in recent months despite wider healthcare sector underperformance referenced in the source summary.
This reset around biopreservation media concentrates BioLife Solutions’ fortunes on a single, more focused revenue engine. This can simplify the story for investors but also heightens exposure to execution risk in one primary product category. Breakeven Date Change • May 18
Forecast breakeven date moved forward to 2026 The 10 analysts covering BioLife Solutions previously expected the company to break even in 2027. New consensus forecast suggests the company will make a profit of US$8.36m in 2026. Earnings growth of 51% is required to achieve expected profit on schedule. Reported Earnings • May 11
First quarter 2026 earnings: EPS and revenues exceed analyst expectations First quarter 2026 results: EPS: US$0.024 (up from US$0.006 in 1Q 2025). Revenue: US$27.5m (up 25% from 1Q 2025). Net income: US$1.19m (up 338% from 1Q 2025). Profit margin: 4.3% (up from 1.2% in 1Q 2025). Revenue exceeded analyst estimates by 7.2%. Earnings per share (EPS) also surpassed analyst estimates by 43%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 100% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Tillkännagivande • May 10
Biolife Solutions, Inc. Reiterates Earnings Guidance for 2026 BioLife Solutions, Inc. reiterated earnings guidance for 2026. For the year, the company expected revenue of $112.5 million to $115.0 million, representing growth of 17% to 20% compared with 2025 revenue from continuing operations; Net income (GAAP) for the full year. Live-nyheter • May 09
BioLife Solutions Returns to Profit and Maintains Guidance as CryoStor Drives Q1 2026 Growth Q1 2026 revenue was US$27.5m, a 25% year-over-year increase, supported by demand for CryoStor biopreservation media. The company returned to profitability with GAAP net income of US$1.2m and reported a 22% non-GAAP adjusted EBITDA margin. BioLife ended the quarter with US$111.5m in cash and reaffirmed full-year 2026 guidance for revenue of US$112.5m to US$115.0m, mid-60% gross margins, GAAP net income and expanding adjusted EBITDA margins.
For you as an investor, the key takeaway is that BioLife is pairing revenue growth with a move back into the black, while still committing capital to its core biopreservation business. CryoStor, which management says holds over 70% share in its market and is used in roughly 250 ongoing U.S. clinical trials, remains central to that story, although a less favorable product mix weighed on gross margin in the quarter.
The reaffirmed 2026 outlook signals that management’s expectations for the year are unchanged after Q1, including the targeted revenue range and profitability metrics. The reported cash balance of US$111.5m indicates the company sees itself as funded for at least the next 12 months of operations and continued investment in biopreservation, which may matter if you are comparing balance sheet strength across cell and gene therapy supply-chain peers. Tillkännagivande • Apr 24
BioLife Solutions, Inc. to Report Q1, 2026 Results on May 07, 2026 BioLife Solutions, Inc. announced that they will report Q1, 2026 results on May 07, 2026 Recent Insider Transactions • Mar 10
Chief Quality & Operations Officer recently sold US$2.0m worth of stock On the 9th of March, Karen Foster sold around 97k shares on-market at roughly US$20.15 per share. This transaction amounted to 46% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Karen's only on-market trade for the last 12 months. Recent Insider Transactions Derivative • Mar 08
Chief Quality & Operations Officer notifies of intention to sell stock Karen Foster intends to sell 97k shares in the next 90 days after lodging an Intent To Sell Form on the 5th of March. If the sale is conducted around the recent share price of US$20.67, it would amount to US$2.0m. Since March 2025, Karen's direct individual holding has increased from 175.66k shares to 210.67k. Company insiders have collectively sold US$3.9m more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Feb 27
Full year 2025 earnings: EPS exceeds analyst expectations Full year 2025 results: US$0.25 loss per share (further deteriorated from US$0.25 loss in FY 2024). Revenue: US$96.2m (up 17% from FY 2024). Net loss: US$12.1m (loss widened 6.5% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 72%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Tillkännagivande • Feb 27
BioLife Solutions, Inc. Provides Earnings Guidance for 2026 BioLife Solutions, Inc. provided earnings guidance for 2026. For the year, the company expected revenue of $112.5 million to $115.0 million, representing growth of 17% to 20% compared with 2025 revenue from continuing operations; Net income (GAAP) for the full year. Tillkännagivande • Feb 17
BioLife Solutions, Inc. to Report Q4, 2025 Results on Feb 26, 2026 BioLife Solutions, Inc. announced that they will report Q4, 2025 results on Feb 26, 2026 Tillkännagivande • Jan 12
BioLife Solutions, Inc. Announces Retirement of Karen Foster as Chief Quality and Operations Officer, Effective March 31, 2026 On January 8, 2026, BioLife Solutions, Inc. announced that Karen Foster, the Chief Quality and Operations Officer, provided notice of her decision to retire from her position as Chief Quality and Operations Officer of the Company, effective March 31, 2026. Recent Insider Transactions • Dec 07
Chief Financial Officer recently sold US$772k worth of stock On the 4th of December, Troy Wichterman sold around 30k shares on-market at roughly US$25.72 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$2.6m. This was Troy's only on-market trade for the last 12 months. Recent Insider Transactions Derivative • Dec 05
Chief Financial Officer notifies of intention to sell stock Troy Wichterman intends to sell 30k shares in the next 90 days after lodging an Intent To Sell Form on the 4th of December. If the sale is conducted around the recent share price of US$25.72, it would amount to US$772k. Since March 2025, Troy's direct individual holding has increased from 160.65k shares to 182.77k. Company insiders have collectively sold US$3.1m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions • Nov 16
CEO & Chairman recently sold US$2.6m worth of stock On the 13th of November, Roderick de Greef sold around 100k shares on-market at roughly US$25.80 per share. This transaction amounted to 56% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Roderick's only on-market trade for the last 12 months. Recent Insider Transactions Derivative • Nov 13
CEO & Chairman notifies of intention to sell stock Roderick de Greef intends to sell 35k shares in the next 90 days after lodging an Intent To Sell Form on the 11th of November. If the sale is conducted around the recent share price of US$26.15, it would amount to US$926k. For the year to December 2018, Roderick's total compensation was 11% salary and 89% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2025, Roderick's direct individual holding has decreased from 231.65k shares to 179.74k. Company insiders have collectively sold US$446k more than they bought, via options and on-market transactions in the last 12 months. Tillkännagivande • Nov 08
BioLife Solutions, Inc. Updates Earnings Guidance for the Fiscal Year 2025 BioLife Solutions, Inc. updated earnings guidance for the fiscal year 2025. Following the sale of its evo cold chain logistics business in early October, BioLife Solutions is updating its 2025 revenue guidance. Total 2025 revenue guidance, adjusted for the sale of evo, is $95.0 million to $96.0 million, representing an increase of 27% - 29% when compared to 2024 continuing operations revenues on a like for like basis. This guidance is based on the following expectations: Cell Processing platform revenue: Raised to $93.0 million to $94.0 million from prior guidance of $91.0 million to $93.0 million, representing year-over-year growth of 26% to 28%. Reported Earnings • Nov 07
Third quarter 2025 earnings: EPS and revenues exceed analyst expectations Third quarter 2025 results: EPS: US$0.013 (up from US$0.037 loss in 3Q 2024). Revenue: US$28.1m (down 8.2% from 3Q 2024). Net income: US$621.0k (up US$2.32m from 3Q 2024). Profit margin: 2.2% (up from net loss in 3Q 2024). Revenue exceeded analyst estimates by 9.3%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Oct 24
BioLife Solutions, Inc. to Report Q3, 2025 Results on Nov 06, 2025 BioLife Solutions, Inc. announced that they will report Q3, 2025 results After-Market on Nov 06, 2025 Recent Insider Transactions Derivative • Oct 18
Independent Director notifies of intention to sell stock Joydeep Goswami intends to sell 9k shares in the next 90 days after lodging an Intent To Sell Form on the 16th of October. If the sale is conducted around the recent share price of US$30.99, it would amount to US$279k. Since March 2025, Joydeep's direct individual holding has decreased from 47.99k shares to 41.11k. Company insiders have collectively sold US$446k more than they bought, via options and on-market transactions in the last 12 months. Tillkännagivande • Oct 08
Peli BioThermal LLC acquired SAVSU Cleo Technologies, LLC from BioLife Solutions, Inc. (NasdaqCM:BLFS) for $25.5 million. Peli BioThermal LLC acquired SAVSU Cleo Technologies, LLC from BioLife Solutions, Inc. (NasdaqCM:BLFS) for $25.5 million on October 7, 2025. The cash purchase price of $25.5 million is subject to certain adjustments. David Zimbalist and Molly Kathleen of EC M&A acted as financial advisor to BioLife Solutions, Inc. Gibson Dunn & Crutcher LLP served as legal counsel to Peli BioThermal LLC and Platinum Equity, LLC.
Peli BioThermal LLC completed the acquisition of SAVSU Cleo Technologies, LLC from BioLife Solutions, Inc. (NasdaqCM:BLFS) on October 7, 2025. Recent Insider Transactions • Aug 28
Chief Commercial Officer recently sold US$255k worth of stock On the 25th of August, Todd Berard sold around 10k shares on-market at roughly US$25.53 per share. This transaction amounted to 7.4% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Major Estimate Revision • Aug 14
Consensus EPS estimates fall by 285%, revenue upgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from US$97.8m to US$101.7m. Forecast EPS reduced from -US$0.093 to -US$0.357 per share. Life Sciences industry in the US expected to see average net income growth of 14% next year. Consensus price target broadly unchanged at US$31.30. Share price rose 23% to US$25.32 over the past week. New Risk • Aug 11
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: US$19m Forecast net loss in 1 year: US$6.0m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company. Reported Earnings • Aug 08
Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2025 results: US$0.33 loss per share (further deteriorated from US$0.15 loss in 2Q 2024). Revenue: US$25.4m (down 10% from 2Q 2024). Net loss: US$15.8m (loss widened 122% from 2Q 2024). Revenue exceeded analyst estimates by 7.2%. Earnings per share (EPS) missed analyst estimates significantly. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Tillkännagivande • Aug 08
BioLife Solutions, Inc. Revises Earnings Guidance for the Year 2025 BioLife Solutions, Inc. revised earnings guidance for the year 2025. For the period, company now expects revenue guidance to $100.0 million to $103.0 million from prior guidance of $95.5 million to $99.0 million, representing growth of 22% to 25% compared with 2024. This guidance is based on the following expectations: Cell Processing platform revenue: Revised to $91.0 million to $93.0 million from prior guidance of $86.5 million to $89.0 million. The revised guidance reflects a year-over-year growth of 24% to 26%. evo and Thaw platform revenue: Affirms guidance of $9.0 million to $10.0 million, reflecting year-over-year growth of 3% to 15%. Tillkännagivande • Jul 25
BioLife Solutions, Inc. to Report Q2, 2025 Results on Aug 07, 2025 BioLife Solutions, Inc. announced that they will report Q2, 2025 results After-Market on Aug 07, 2025 Tillkännagivande • Jul 09
BioLife Solutions, Inc., Annual General Meeting, Aug 20, 2025 BioLife Solutions, Inc., Annual General Meeting, Aug 20, 2025. Major Estimate Revision • May 15
Consensus EPS estimates upgraded to US$0.092 loss The consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -US$0.135 to -US$0.092 per share. Revenue forecast steady at US$97.8m. Life Sciences industry in the US expected to see average net income growth of 12% next year. Consensus price target of US$31.22 unchanged from last update. Share price rose 3.3% to US$22.05 over the past week. Reported Earnings • May 09
First quarter 2025 earnings: EPS and revenues exceed analyst expectations First quarter 2025 results: US$0.01 loss per share (improved from US$0.093 loss in 1Q 2024). Revenue: US$23.9m (down 11% from 1Q 2024). Net loss: US$448.0k (loss narrowed 89% from 1Q 2024). Revenue exceeded analyst estimates by 7.7%. Earnings per share (EPS) also surpassed analyst estimates by 81%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth. Tillkännagivande • May 09
Biolife Solutions, Inc. Affirms Earnings Guidance for the Year 2025 BioLife Solutions, Inc. affirmed earnings guidance for the year 2025. For the period, company expects revenue of $95.5 million to $99.0 million, representing growth of 16% to 20% compared with 2024. This is based on expectations for Cell Processing platform and evo and Thaw platform, as follows: Cell Processing platform: $86.5 million to $89.0 million, reflecting year-over-year growth of 18% to 21%. evo and Thaw platform: $9.0 million to $10.0 million, reflecting year-over-year growth of 3% to 15%. Management expects reduction in net loss (GAAP). Tillkännagivande • Apr 30
BioLife Solutions, Inc. to Report Q1, 2025 Results on May 08, 2025 BioLife Solutions, Inc. announced that they will report Q1, 2025 results After-Market on May 08, 2025 Tillkännagivande • Apr 07
BioLife Solutions, Inc. (NasdaqCM:BLFS) acquired 90% stake in PanTHERA CryoSolutions Inc for $21.53 million. BioLife Solutions, Inc. (NasdaqCM:BLFS) acquired 90% stake in PanTHERA CryoSolutions Inc. for $21.53 million on April 7, 2025. A cash consideration of $9.3 million will be paid by BioLife Solutions, Inc. The consideration consists of 0.24 million common equity of BioLife Solutions, Inc. to be issued for common equity of PanTHERA CryoSolutions Inc. BioLife Solutions, Inc. will pay an earnout/contingent payment of $7.2 million cash. As part of consideration, $16.5 million is paid towards common equity of PanTHERA CryoSolutions Inc.
BioLife Solutions, Inc. (NasdaqCM:BLFS) completed the acquisition of 90% stake in PanTHERA CryoSolutions Inc. on April 7, 2025. Tillkännagivande • Mar 18
Biolife Solutions, Inc. Announces Board Changes BioLife Solutions, Inc. announced the appointment of Cathy Coste to its board of directors. Ms. Coste will serve as chair of the audit committee, replacing Joydeep Goswami, who will remain a company director and member of the audit committee. Ms. Coste retired from Deloitte in 2020, where she most recently was a senior partner and life sciences industry executive leader. With Deloitte for more than 30 years, she served in corporate and professional services positions, ultimately leading global finance, internal audit and operations teams while participating in more than 200 audit committee meetings. Previously she worked at Mervyn's, including responsibility in accounting, FP&A and operations. Ms. Coste is a director of Biomerica, Inc., Minerva Surgical, Inc. (a public company that went private in 2024) and Renalytix plc, serving as audit committee chair for each. She holds a B.A. in business administration-accounting from California State University, Hayward, and completed Harvard Business School's Corporate Director's Certificate Program. She is a licensed Certified Public Accountant. Recent Insider Transactions Derivative • Mar 13
Chief Human Resources Officer notifies of intention to sell stock Sarah Aebersold intends to sell 7k shares in the next 90 days after lodging an Intent To Sell Form on the 12th of March. If the sale is conducted around the recent share price of US$26.62, it would amount to US$195k. Since June 2024, Sarah's direct individual holding has decreased from 64.68k shares to 59.91k. Company insiders have collectively sold US$1.1m more than they bought, via options and on-market transactions in the last 12 months. Major Estimate Revision • Mar 10
Consensus estimates of losses per share improve by 17% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from US$95.5m to US$97.0m. EPS estimate increased from -US$0.162 per share to -US$0.135 per share. Life Sciences industry in the US expected to see average net income growth of 13% next year. Consensus price target broadly unchanged at US$31.33. Share price rose 5.4% to US$25.83 over the past week. Reported Earnings • Mar 03
Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2024 results: US$0.25 loss per share (improved from US$1.52 loss in FY 2023). Revenue: US$82.3m (down 43% from FY 2023). Net loss: US$11.4m (loss narrowed 83% from FY 2023). Revenue missed analyst estimates by 17%. Earnings per share (EPS) exceeded analyst estimates by 3.9%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Mar 03
BioLife Solutions, Inc. Provides Earnings Guidance for the Year 2025 BioLife Solutions, Inc. provided earnings guidance for the year 2025. For the period, company expects revenue of $95.5 million to $99.0 million, representing growth of 16% to 20% compared with 2024. This is based on expectations for Cell Processing platform and evo and Thaw platform, as follows: Cell Processing platform: $86.5 million to $89.0 million, reflecting year-over-year growth of 18% to 21%. evo and Thaw platform: $9.0 million to $10.0 million, reflecting year-over-year growth of 3% to 15%. Management expects reduction in net loss (GAAP). Tillkännagivande • Feb 21
BioLife Solutions, Inc. to Report Q4, 2024 Results on Mar 03, 2025 BioLife Solutions, Inc. announced that they will report Q4, 2024 results Pre-Market on Mar 03, 2025 Major Estimate Revision • Jan 14
Consensus revenue estimates decrease by 13%, EPS upgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$107.8m to US$94.0m. EPS estimate increased from -US$0.537 to -US$0.523 per share. Life Sciences industry in the US expected to see average net income growth of 18% next year. Consensus price target up from US$30.20 to US$31.00. Share price fell 3.1% to US$26.27 over the past week. Buy Or Sell Opportunity • Dec 23
Now 20% undervalued Over the last 90 days, the stock has risen 6.4% to US$26.38. The fair value is estimated to be US$33.03, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.1% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 32% in a year. Earnings are forecast to grow by 74% in the next year. Tillkännagivande • Dec 16
Biolife Solutions Inc. Appoints Tony J. Hunt to Its Board of Directors, Effective from January 2, 2025 BioLife Solutions, Inc. announced the appointment of Tony J. Hunt, Executive Chairman of Repligen Corporation and a recognized leader in bioprocessing innovation, to its board of directors effective January 2, 2025. His appointment increases board membership to six. Prior to being named Executive Chairman of Repligen in September 2024, Mr. Hunt served as CEO and director for nine years, having joined the firm in 2014 as Chief Operating Officer. Earlier, he was President of Bioproduction at Life Technologies, a global life sciences company acquired by Thermo Fisher Scientific in 2014. He joined Life Technologies in 2008 as General Manager of Bioproduction Chromatography and Pharma Analytics. From 2000 to 2008, Mr. Hunt was Senior Director of Pharma Programs at Applied Biosystems, where he launched the Pharma Analytics business that became part of the Bioproduction platform at Life Technologies.He holds a bachelor's degree with honors in microbiology and a master's degree in biotechnology from the University of Galway, and an MBA from the Questrom School of Business at Boston University. Mr. Hunt serves on the board of directors of 908 Devices Inc., a publicly traded innovator of handheld and desktop devices for chemical analysis. Buy Or Sell Opportunity • Dec 05
Now 23% undervalued Over the last 90 days, the stock has risen 5.8% to US$25.18. The fair value is estimated to be US$32.69, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.1% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 18% in 2 years. Earnings are forecast to grow by 98% in the next 2 years. Recent Insider Transactions Derivative • Nov 20
Chairman of Scientific Advisory Board exercised options and sold US$191k worth of stock On the 15th of November, Aby Mathew exercised 10k options at a strike price of around US$2.06 and sold these shares for an average price of US$21.16 per share. This trade did not impact their existing holding. Since December 2023, Aby's direct individual holding has increased from 276.67k shares to 317.05k. Company insiders have collectively sold US$1.3m more than they bought, via options and on-market transactions in the last 12 months. Tillkännagivande • Nov 15
Standex International Corporation (NYSE:SXI) acquired Custom Biogenic Systems Inc. from BioLife Solutions, Inc. (NasdaqCM:BLFS) for $6.2 million. Standex International Corporation (NYSE:SXI) acquired Custom Biogenic Systems Inc. from BioLife Solutions, Inc. (NasdaqCM:BLFS) for $6.2 million on November 14, 2024. The transaction is being financed from Standex's existing cash balance. In its first year of ownership, the Company expects the acquisition to be accretive to its earnings. CBS will be reported as part of Standex's Scientific business segment. In calendar year 2024, Custom Biogenic Systems estimates revenues of approximately $15 million.
Standex International Corporation (NYSE:SXI) completed the acquisition of Custom Biogenic Systems Inc. from BioLife Solutions, Inc. (NasdaqCM:BLFS) on November 14, 2024. Reported Earnings • Nov 13
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Third quarter 2024 results: US$0.037 loss per share (improved from US$0.67 loss in 3Q 2023). Revenue: US$30.6m (down 8.3% from 3Q 2023). Net loss: US$1.70m (loss narrowed 94% from 3Q 2023). Revenue exceeded analyst estimates by 20%. Earnings per share (EPS) also surpassed analyst estimates by 50%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 22% per year. Tillkännagivande • Nov 13
BioLife Solutions, Inc. Revises Earnings Guidance for the Year 2024 BioLife Solutions announced that the company is revising its 2024 earnings guidance to $98.0 million to $100.0 million from prior guidance of $99.0 million to $101.0 million primarily to reflect the revenue impact of the divestiture of SciSafe on November 12, 2024. This guidance also reflects updated expectations for BioLife's Cell Processing product line and Biostorage and Services, which includes results from its ThawSTAR product line and does not include revenue from the freezer product line (GCI and CBS) or SciSafe after November 12, 2024. Tillkännagivande • Nov 12
An undisclosed buyer acquired SciSafe Holdings, Inc. from BioLife Solutions, Inc. (NasdaqCM:BLFS). An undisclosed buyer acquired SciSafe Holdings, Inc. from BioLife Solutions, Inc. (NasdaqCM:BLFS) for US $73 million on November 12, 2024. A cash consideration of $73 million will be paid by the buyer. In conjunction with this transaction, Todd Berard, BioLife's Chief Marketing Officer, will assume all sales and marketing functions for the Company in the newly created position of Chief Commercial Officer. Garrie Richardson, previously BioLife's Chief Revenue Officer for the last year, will join a now independent SciSafe as Chief Executive Officer. Stephens Inc. acted as financial advisor for BioLife Solutions, Inc. K&L Gates LLP acted as legal advisor for BioLife Solutions, Inc.
An undisclosed buyer completed the acquisition of SciSafe Holdings, Inc. from BioLife Solutions, Inc. (NasdaqCM:BLFS) on November 12, 2024. Tillkännagivande • Nov 01
BioLife Solutions, Inc. to Report Q3, 2024 Results on Nov 12, 2024 BioLife Solutions, Inc. announced that they will report Q3, 2024 results After-Market on Nov 12, 2024 Recent Insider Transactions Derivative • Oct 18
Chairman of Scientific Advisory Board exercised options and sold US$423k worth of stock On the 16th of October, Aby Mathew exercised 20k options at a strike price of around US$2.06 and sold these shares for an average price of US$23.23 per share. This trade did not impact their existing holding. Since December 2023, Aby's direct individual holding has increased from 276.67k shares to 317.72k. Company insiders have collectively sold US$1.1m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Sep 20
Chairman of Scientific Advisory Board notifies of intention to sell stock Aby Mathew intends to sell 103k shares in the next 90 days after lodging an Intent To Sell Form on the 18th of September. If the sale is conducted around the recent share price of US$23.45, it would amount to US$2.4m. Since September 2023, Aby's direct individual holding has increased from 273.12k shares to 317.72k. There has only been one transaction (US$190k sale) from insiders over the last 12 months. Buy Or Sell Opportunity • Sep 17
Now 25% undervalued Over the last 90 days, the stock has risen 17% to US$23.45. The fair value is estimated to be US$31.48, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 2.1% in 2 years. Earnings are forecast to grow by 98% in the next 2 years. Buy Or Sell Opportunity • Aug 22
Now 22% undervalued Over the last 90 days, the stock has risen 13% to US$24.45. The fair value is estimated to be US$31.48, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 2.1% in 2 years. Earnings are forecast to grow by 98% in the next 2 years. New Risk • Aug 12
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$64m Forecast net loss in 2 years: US$8.2m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$8.2m net loss in 2 years). Shareholders have been diluted in the past year (6.1% increase in shares outstanding). Breakeven Date Change • Aug 12
No longer forecast to breakeven The 9 analysts covering BioLife Solutions no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$7.39m in 2026. New consensus forecast suggests the company will make a loss of US$18.3m in 2026. Price Target Changed • Aug 12
Price target increased by 7.4% to US$27.33 Up from US$25.44, the current price target is an average from 9 analysts. New target price is 8.3% above last closing price of US$25.25. Stock is up 100% over the past year. The company is forecast to post a net loss per share of US$0.52 next year compared to a net loss per share of US$1.52 last year. Reported Earnings • Aug 09
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2024 results: US$0.15 loss per share (improved from US$0.23 loss in 2Q 2023). Revenue: US$28.3m (down 28% from 2Q 2023). Net loss: US$7.15m (loss narrowed 30% from 2Q 2023). Revenue exceeded analyst estimates by 18%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings. Price Target Changed • Aug 09
Price target increased by 7.2% to US$26.56 Up from US$24.78, the current price target is an average from 9 analysts. New target price is 5.2% above last closing price of US$25.25. Stock is up 108% over the past year. The company is forecast to post a net loss per share of US$0.52 next year compared to a net loss per share of US$1.52 last year. Tillkännagivande • Aug 09
BioLife Solutions, Inc. Updates Revenue Guidance for the Year 2024 BioLife Solutions, Inc. updated revenue guidance for the year 2024. For the year, the company expects revenue to be $99.0 million to $101.0 million from prior guidance of $95.5 million to $100.0 million. This guidance is based on expectations for BioLife's Cell Processing and Biostorage Services platforms, which now include results from its ThawSTAR® product line and do not include revenue from the freezer product line (GCI and CBS). Tillkännagivande • Jul 26
BioLife Solutions, Inc. to Report Q2, 2024 Results on Aug 08, 2024 BioLife Solutions, Inc. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024 Buy Or Sell Opportunity • Jul 18
Now 22% undervalued Over the last 90 days, the stock has risen 35% to US$21.45. The fair value is estimated to be US$27.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has declined by 49%. Revenue is forecast to decline by 7.3% in 2 years. Earnings are forecast to grow by 84% in the next 2 years. Tillkännagivande • Jun 08
BioLife Solutions, Inc., Annual General Meeting, Aug 01, 2024 BioLife Solutions, Inc., Annual General Meeting, Aug 01, 2024. Tillkännagivande • May 30
BioLife Solutions Introduces the CellSeal CryoCase™ at International Society for Cell & Gene Therapies (ISCT) Conference in Vancouver BioLife Solutions, Inc. announced the introduction of the CryoCase, an addition to its CellSeal product line. Expected to be released to CGT developers in August, the CryoCase is available for demonstration at this week's ISCT event in Vancouver, Canada. Early product evaluators stated that the CryoCase's volume versatility, rigid and protective structure, and fill and retrieval port designs, allows for easy integration with their current systems generating improved throughput and streamlined procedures. The CryoCase is the first ever cryo-compatible rigid container designed for closed-system fill and retrieval for larger volumes of fluid (<75mL). The container is transparent, enabling improved end user compliance with USP 790, USP 1790, and other international visible inspection methods, and manufactured under strict environmental and processing controls designed to limit common sources of particulates in single-use disposable manufacturing. Early user testing has shown comparable cell viability and recovery for multiple cell types compared to storage in existing bags and drop testing in a frozen state demonstrates high resistance to leaks or fractures. Initial testing indicates that the CryoCase may materially reduce or eliminate particulates inherent in cryopreservation bags. CryoCase samples are now available for testing. Major Estimate Revision • May 17
Consensus estimates of losses per share improve by 47% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from US$100.8m to US$109.1m. EPS estimate increased from -US$1.06 per share to -US$0.56 per share. Life Sciences industry in the US expected to see average net income growth of 20% next year. Consensus price target up from US$23.13 to US$24.78. Share price rose 12% to US$21.96 over the past week. Breakeven Date Change • May 15
No longer forecast to breakeven The 7 analysts covering BioLife Solutions no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$63.0m in 2026. New consensus forecast suggests the company will make a loss of US$7.00m in 2026. Price Target Changed • May 13
Price target increased by 7.8% to US$23.88 Up from US$22.14, the current price target is an average from 8 analysts. New target price is 16% above last closing price of US$20.66. Stock is up 6.2% over the past year. The company is forecast to post a net loss per share of US$0.63 next year compared to a net loss per share of US$1.52 last year. Reported Earnings • May 11
First quarter 2024 earnings released: US$0.23 loss per share (vs US$0.32 loss in 1Q 2023) First quarter 2024 results: US$0.23 loss per share (improved from US$0.32 loss in 1Q 2023). Revenue: US$31.7m (down 16% from 1Q 2023). Net loss: US$10.2m (loss narrowed 26% from 1Q 2023). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Tillkännagivande • May 01
BioLife Solutions, Inc. to Report Q1, 2024 Results on May 09, 2024 BioLife Solutions, Inc. announced that they will report Q1, 2024 results After-Market on May 09, 2024 Breakeven Date Change • Apr 23
Forecast breakeven date pushed back to 2026 The 9 analysts covering BioLife Solutions previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 41% per year to 2025. The company is expected to make a profit of US$7.39m in 2026. Average annual earnings growth of 61% is required to achieve expected profit on schedule. 